A uterine fibroid treatment from Myovant Sciences met its goals in a second late-stage trial, setting the stage for Food and Drug Administration approval and competition with a pharmaceutical giant.

The drug, relugolix, significantly reduced menstrual blood loss, the most common symptom of uterine fibroids, and beat placebo on six other metrics including pain and quality of life, according to data released Tuesday. About 71% of women who took the daily pill responded to the therapy, experiencing at least a 50% reduction in blood loss over 24 weeks and falling below the FDA’s definition of heavy menstrual bleeding. The drug’s safety profile was similar to that of placebo, including on the key metric of bone density.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy